S. Whitman

Guido Marcucci, Stefano Volinia, Jessica Kohlschmidt, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SOS1 mutations are rare in human malignancies: Implications for Noonan syndrome patients

M. Loh, M. Caligiuri, M. Meyerson, 2008, Genes, chromosomes & cancer.

Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia.

Guido Marcucci, Christoph Plass, Thomas D. Schmittgen, 2008, Cancer research.

Expression in Acute Myeloid Leukemia α Epigenetic Modification of CCAAT / Enhancer Binding Protein

Thomas D. Schmittgen, C. Bloomfield, C. Plass, 2008 .

DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.

M. Caligiuri, C. Bloomfield, C. Plass, 2008, Blood.

Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells

M. Grever, J. Byrd, C. Plass, 2003, Leukemia.

Sp1/NF κ B/HDAC/ miR-29b Regulatory Network in KIT-driven Myeloid Leukemia

M. Caligiuri, C. Bloomfield, J. Byrd, 2010 .

Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Importance of MN 1 Transcript Levels , and Biologic Insights From MN 1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia : A Cancer and Leukemia Group B Study

M. Caligiuri, C. Bloomfield, M. Radmacher, 2009 .

The Mll partial tandem duplication: differential, tissue-specific activity in the presence or absence of the wild-type allele.

M. Caligiuri, G. Marcucci, S. Whitman, 2008, Blood.

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, J. Byrd, 2013, Blood.

Dose escalation of lenalidomide in relapsed or refractory acute leukemias.

M. Grever, J. Byrd, R. Garzon, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010, Blood.

miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2012, Blood.

Wilms Tumor 1 (WT1) Gene Mutations Predict Poor Outcome in Adults with Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): A Cancer and Leukemia Group B (CALGB) Study.

M. Caligiuri, C. Bloomfield, P. Paschka, 2007 .

A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia

M. Caligiuri, C. Bloomfield, K. Metzeler, 2013, Leukemia.

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Blood.

myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study cytogenetically normal patients younger than 60 years with acute markers, poor outcome, and a distinct gene-expression signature in High BAALC expression associates with other molecular prognostic

M. Ross, M. Radmacher, P. Paschka, 2013 .

Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.

C. Bloomfield, Yue-zhong Wu, K. Metzeler, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO

Salam A. Assi, C. Bloomfield, N. Nassar, 2016, Leukemia.

Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

M. Caligiuri, C. Bloomfield, P. Paschka, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2008, Blood.

BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.

M. Caligiuri, C. Bloomfield, A. de la Chapelle, 2003, Blood.

The partial nontandem duplication of the MLL (ALL1) gene is a novel rearrangement that generates three distinct fusion transcripts in B-cell acute lymphoblastic leukemia.

M. Caligiuri, C. Bloomfield, N. Zeleznik-Le, 2001, Cancer research.

Group B Study leukemia patients with normal cytogenetics: a Cancer and Leukemia BAALC expression predicts clinical outcome of de novo acute myeloid

M. Caligiuri, R. Larson, D. Baldus, 2013 .

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.

Guido Marcucci, Jessica Kohlschmidt, Heiko Becker, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Blood.

Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Guido Marcucci, Heiko Becker, Sebastian Schwind, 2010, Blood.

GAS6 expression identifies high-risk adult AML patients: potential implications for therapy

Klaus H. Metzeler, Guido Marcucci, Stefano Volinia, 2013, Leukemia.

Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8

M. Caligiuri, M. Radmacher, K. Metzeler, 2014, Leukemia.

Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study.

C. Bloomfield, M. Radmacher, P. Paschka, 2009 .

Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.

M. Caligiuri, G. Lozanski, K. Heider, 2016, Blood.

High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.

C. Bloomfield, P. Paschka, R. Larson, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia.

M. Caligiuri, J. Byrd, R. Baiocchi, 2005, Blood.

Low Meningioma 1 (MN1) gene expression to predict outcome in cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) study

C. Bloomfield, P. Paschka, R. Larson, 2008 .

Cellular Uptake and Intracellular Levels of the Bcl-2 Antisense G3139 in Cultured Cells and Treated Patients with Acute Myeloid Leukemia

M. Caligiuri, M. Grever, J. Byrd, 2005, Clinical Cancer Research.

Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease.

M. Caligiuri, G. Marcucci, S. Whitman, 2013, Blood.

Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts)

C. Bloomfield, Yue-zhong Wu, K. Metzeler, 2011 .

The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia

M. Caligiuri, C. Bloomfield, M. Radmacher, 2012, Leukemia.

miR-3151 Interplays With its Host Gene BAALC and Independently Impacts on Outcome of Older Patients With Cytogenetically Normal Acute Myeloid Leukemia by Direct Deregulation of TP53

M. Caligiuri, C. Bloomfield, M. Radmacher, 2014 .

SPARC contributes to Leukemia Growth and Aggressive Disease in Acute Myeloid Leukemia (AML)

M. Caligiuri, C. Bloomfield, K. Metzeler, 2012 .

Protein Kinase CβII Activation by 1-β-d-Arabinofuranosylcytosine Is Antagonistic to Stimulation of Apoptosis and Bcl-2α Down-regulation*

F. Civoli, L. Daniel, S. Whitman, 1997, The Journal of Biological Chemistry.

Efficacy and safety of an anti-FLT3 antibody (LY3012218) in patients with relapsed acute myeloid leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015 .

Promotes Gene Expression by Disrupting the DNA Binding of the AML1/ETO and HDAC1 Repressor Complex.

G. Marcucci, T. Shen, D. Perrotti, 2004 .

myeloid leukemia in acute microRNA-181a up-regulates expression of the antileukemic -p30 protein α Lenalidomide-mediated enhanced translation of C/EBP

C. Bloomfield, J. Byrd, L. J. Lee, 2013 .

Ramasamy myeloid leukemia in acute microRNA-181 a upregulates expression of the antileukemic-p 30 protein α Lenalidomide-mediated enhanced translation of C / EBP

Wu, Krzysztof, Santhanam, 2012 .

Protein kinase CbetaII activation by 1-beta-D-arabinofuranosylcytosine is antagonistic to stimulation of apoptosis and Bcl-2alpha down-regulation.

F. Civoli, L. Daniel, S. Whitman, 1997, The Journal of biological chemistry.

Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [≥60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2009 .

Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML

M. Caligiuri, R. Bundschuh, S. Kulp, 2013, Leukemia.

Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study

M. Caligiuri, C. Bloomfield, M. Radmacher, 2010 .

Outcome prediction in adult core binding factor (CBF) acute myeloid leukemia (AML) with gene expression profiling: A Cancer and Leukemia Group B (CALGB) study

C. Bloomfield, M. Radmacher, P. Paschka, 2007 .

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, J. Byrd, 2013, Blood.

University of Birmingham UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO

Salam A. Assi, C. Bloomfield, C. Bonifer, 2015 .

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

M. Caligiuri, C. Bloomfield, M. Radmacher, 2011, Blood.

Coordinate Transcriptional and Translational Regulation of Ferritin in Response to Oxidative Stress

F. Torti, S. Torti, S. Whitman, 2000, Molecular and Cellular Biology.

MYELOID NEOPLASIA Eradicating acute myeloid leukemia in a Mll PTD/wt : Flt3 ITD/wt murine model: a path to novel therapeutic approaches for human disease

M. Caligiuri, G. Marcucci, S. Whitman, 2013 .

Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.

M. Caligiuri, C. Bloomfield, J. Byrd, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML).

C. Bloomfield, M. Radmacher, R. Larson, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline

M. Caligiuri, C. Bloomfield, K. Metzeler, 2013, Haematologica.

Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia.

M. Caligiuri, C. Bloomfield, Lisheng Wang, 2007, Blood.